Precision Biosciences (DTIL) Profit After Tax (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Profit After Tax of -$18.4 million for Q1 2026, up 10.33% year-over-year from -$16.7 million in Q1 2025, and down 195.81% quarter-over-quarter from $19.2 million in Q4 2025.
Precision Biosciences (DTIL) Profit After Tax (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Profit After Tax for 9 consecutive years, with -$18.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 10.33% year-over-year to -$18.4 million; the TTM figure through Mar 2026 stood at -$44.5 million (down 102.33% YoY), while the FY2025 annual figure was -$46.6 million, down 750.33% from the prior year.
- Profit After Tax fell to -$18.4 million in Q1 2026 per DTIL's latest filing, from $19.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at $32.7 million in Q2 2024 and bottomed at -$58.2 million in Q4 2022.
- Historically, Profit After Tax has averaged -$14.9 million across 5 years, with a median of -$17.7 million in 2024.
- Annual changes were most pronounced in 2024 — Profit After Tax soared 375.41% — and 2025, when it sank 339.46%.
- Precision Biosciences' Profit After Tax stood at -$58.2 million in 2022, then jumped by 76.9% to -$13.4 million in 2023, then tumbled by 32.09% to -$17.7 million in 2024, then jumped by 208.47% to $19.2 million in 2025, then tumbled by 195.81% to -$18.4 million in 2026.
- Business Quant data shows DTIL's Profit After Tax at -$18.4 million in Q1 2026, $19.2 million in Q4 2025, and -$21.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -32.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.65 Mn |
| Mar 31, 2026 | -18.44 Mn |
| Dec 31, 2025 | 19.25 Mn |
| Sep 30, 2025 | -21.77 Mn |
| Jun 30, 2025 | -23.52 Mn |
| Mar 31, 2025 | -20.57 Mn |
| Dec 31, 2024 | -17.75 Mn |
| Sep 30, 2024 | -16.43 Mn |
| Jun 30, 2024 | 32.75 Mn |
| Mar 31, 2024 | 8.59 Mn |
| Dec 31, 2023 | -13.43 Mn |
| Sep 30, 2023 | -12.11 Mn |
| Jun 30, 2023 | -11.89 Mn |
| Mar 31, 2023 | -25.06 Mn |
| Dec 31, 2022 | -58.16 Mn |
| Sep 30, 2022 | -15.69 Mn |
| Jun 30, 2022 | -31.04 Mn |
| Mar 31, 2022 | -28.17 Mn |
| Dec 31, 2021 | -22.29 Mn |
| Sep 30, 2021 | -11.28 Mn |